Is GILD's remdesivir relevant to this COVID-19 Vascular MOA? Amarin's Vascepa could be:
SALK Institute and NIH research report
The tested cocktails still require (intravenous) remdesivir to stop SARS-CoV-2 replication. What's badly needed is an all-oral regimen.
GILD Investor Relations
Viral Disease Pipeline Phase 1 Phase 2 Phase 3 NDA/BLA/MAA HIV Biktarvy HIV treatment pediatric1 Capsid inhibitor (GS-6207)
HIV HTE HIV treatment naïve Vesatolimod (GS-9620, TLR-7 agonist) HIV cure Elipovimab (GS-9722, bNAb)
HIV cure HBV Selgantolimod
(GS-9688,TLR-8 agonist) HBV cure PD-L1 inhibitor (GS-4224) HBV cure 1 Biktarvy HIV treatment pediatric label extension.
2 Registrational for heavily treatment-experienced (HTE) patients.
Humanigen Reports Positive Phase 3 Topline Results Demonstrating That Lenzilumab™ Improves Survival Without Need for Mechanical Ventilation in Hospitalized Patients With COVID-19
Lenzilumab improved the relative likelihood of survival without need for invasive mechanical ventilation (IMV) by 54%, achieving the primary endpoint of the Phase 3 study
Clinical improvement was observed over and above other treatments, including steroids and/or remdesivir
BURLINGAME, Calif.--(BUSINESS WIRE)-- Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate, lenzilumab, today announced positive topline results from its Phase 3 clinical trial evaluating the efficacy and safety of lenzilumab in patients hospitalized with COVID-19. Trial results showed that patients who received lenzilumab and other treatments, including steroids and/or remdesivir, had a 54% greater relative likelihood of survival without the need for IMV compared with patients receiving placebo and other treatments. These results are statistically significant.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210329005301/en/
There are good/very good treatments but not yet FDA approved for covid 19
It are not vaccines but one vaccine ( Astrazeneca) that are on hold but not cancelled. in Europe
Covid-No good treatments after 1 year?
Nothing but vaccines that are getting cancelled all over Europe. And those that aren't, how long do they last? A few months/weeks??
Meanwhile, crisis mode in Brazil as Brazilians begging for a treatment that works.
Brazil plunges into deadliest chapter of it's pandemic
March 13, 2021
Except for GILD, all 2 dozen or so of my investments have gains so far today. That is , except for SDOW, which is a little crash insurance in my portfolio.
GILD has been a long hold that has gone nowhere for a few years for me. I guess I'll sell it when it finally rallies a little. Their culture is a little too woke for me anyway. I mean, some social conscience is a good thing, but one can go too far.
The Gild price is dropping recently. It has a lot of good news as you posted and 3/5/2021, FDA will have a meeting to discussion of the drug ( Axicabtagene ciloleucel ) for Getting Label Expansion For Cell-Therapy to Treat Lymphoma. Is some thing wrong?
maybe a partnership would be "necessary"?
Gilead Sciences Inc (GILD)
64.38 ? -0.85 (-1.30%)
Volume: 6,054,624 @02/19/21 7:59:23 PM EST
Bid Ask Day's Range
64.38 64.72 64.27 - 65.22
GILD Detailed Quote
GILD was hash tagged by our COO on Twitter and new development points us toward ur direction. Hopefully, GILD takes down their previous partner and tamiflu with ENZC ITV-1. Just a thought and my opinion.
$enzc. $GILD investors. You might want to check out this PR today. From googling found that tamiflu used to be owned by @Gilead until some bad blood. Key here is our drug was tested against tamiflu and was 20x less toxic with same efficacy. #payback maybe? https://t.co/yixxbz7EgL— SimbaJ22 (@SimbaJ22) February 16, 2021
Little chance of that
In November 2019, Dew Diligence posted the following on the BT Value board about a GILD/Amarin "collaboration":
…GILD added Vascepa to NASH trial…
An earlier article in streetinsider.com was guilty of suggesting that GILD had some kind of partnership with AMRN, so an updated article was posted to rebut this notion:
A recent posting at clinicaltrials.gov, pointed out by Raymond James' Gilead analyst Steven Seedhouse, showed that a cohort was added to the protocol that includes Amarin's Vascepa along with firsocostat (ACC inhibitor) and cilofexor (FXR agonist).
The analyst thinks Vascepa was added to compensate for the increase in TGs caused by firsocostat. He said this is similar to how statins compensate for LDL-C increase by FXR agonists.
Seedhouse said he is not aware of any formal collaboration between Amarin and Gilead, so he presumes Gilead is purchasing drug material."
I am trying to obtain any news of what has happened with respect to results from the added Vascepa mentioned in the above-quoted material. Comments from anyone with specific knowledge would be appreciated. Our portfolios contain both GILD and AMRN.
The FDA approved Vascepa for reducing the risk from various aspects of CVDs last December 2020.
Remdesevir has FDA approval! Check your facts before spamming another board for a different play.
With as many doses that have been produced and ordered by the world by Gilead's extensive production network, it will take years for your B to ramp up and see meaningful revenue results when comparing the 2.
Having said that, I am a buyer of I*** based on Ph 2 results which have not been announced to have started yet, only plans to start. Initial dosing would be something to put out and that was supposed to have happened last week.
Gilead’s Remdesivir AKA Velkury has emergency use authorization (EUA) n the United States and just barely reduces hospital length of stay in some patients and it is questionable if it really reduces mortality to any degree. It has NOT received FDA approval because it hasn’t performed in real life practice. As soon as the FDA sees another drug that can reduce length of stay and save some lives, Remdesivir will lose it’s EUA and it’s share of the market which is pretty much all of it.
Remdesivir needs Brilacidin, but it is abundantly clear that Brilacidin does not need Remdesivir. I anticipate the placebos will be whatever the standard of care is being used in the respective country as it is unethical to withhold treatment in a life or death situation. Brilacidin will go head to head vs. Remdesivir and we all know who will win.
A national Covid strategy.
A good part of the orders Biden has signed so far relate to the coronavirus pandemic. The Current administration is building a muscular federal response to the crisis, a major change from Trump’s decentralized approach. The Biden plan will include a Pandemic Testing Board to establish unified standards across the country and boost supplies, which are still inadequate. There will be a Federal vaccination campaign, with federaly run mass vaccination centers and mobile units for rural areas. States and cities will get more funding and personnel for speedy vaccine deployment. The Biden administration will rebuild scientific agencies that Trump shackled or gutted. It will also establish procedures for reopening schools and provide more resources for local school districts.
It’s a mystery why the previous administration didn’t take these types of steps early in the pandemic. Public health experts and business leaders have stressed all along that massively scaled testing is crucial to safely operating businesses and reopening those forced to close. Vaccines will ultimately reduce the need for testing, but the vaccine rollout has been slow since it kicked off in December, with widespread immunity not likely until 2022 at the current pace.
Final Score Brilacidin 426, Remdesivir 130 .... a complete BLOW OUT!
Statistical Facts in Medical Science do matter!
BRILACIDIN SI *426*. Some keep babbling about safety.
Government RBLs recently declared BRILACIDIN has a SI of *426*.
Everyone was hoping to at least equal Gileads Remdesivir number of 129.87. A number good enough for FDA APPROVAL and 2 billion in revenues last year.
The higher the SI ratio the more EFFECTIVE and SAFE a drug would be during treatment for viral infections.
SAFE and EFFECTIVE are the key words.
The SI of a compound IS widely accepted parameter used to express a compounds efficacy in the INHIBITION of virus replication.
BRILACIDIN *426* efficiency has a 97% kill rate of the virus in lab testing. When combined with Remdesivir's 129 the kill rate did slightly jump up to 99.85%.
Simply put, peple would being saved at this very moment IF Gilead
was owner of BRILACIDIN *426*.
Seeing is believing. BRILACIDIN did so well that the RBLs STATED that BRILACIDIN should be lab tested against a host of other viruses.
You can believe what the major UNIVERSITIES, Government RBLs and highly honored scientists are saying after testing BRILACIDIN in the labs or you can belive the unsubstantiated claims of the other side. The agenda of the first group is to better society and bring help to the medical community. I can't say what the agenda is of the other side. God only knows..
BRILACIDIN *426* the SAFE ALTERNAIVE to many future ailments...
$GILD upgraded to $83.00
Gilead Sciences or Biogen: Which Biotech Stock is a Better Pick for 2021?
$GILD [value and yield, consider these five undervalued dividend stocks to buy:]
Gilead Sciences (NASDAQ:GILD)
Roche is one of the worst Pharma Companies to work for.
If True, watch Gilead lose the people that got them here.
This is like Frank Lorenzo buying up Eastern Airlines snd others.
Some chat, iRoche is the one killing the stock
NIH study uncovers blood vessel damage and inflammation in COVID-19 patients’ brains but no infection
Results from a study of 19 deceased patients suggests brain damage is a byproduct of a patient’s illness.
Scan of deceased COVID-19 patient’s brain
NIH researchers consistently found blood vessel damage in the brains of COVID-19 patients but no signs of SARS-CoV-2 infections. Arrows point to light and dark spots that are indicative of blood vessel damage observed in the study. NIAID
In an in-depth study of how COVID-19 affects a patient’s brain, National Institutes of Health researchers consistently spotted hallmarks of damage caused by thinning and leaky brain blood vessels in tissue samples from patients who died shortly after contracting the disease. In addition, they saw no signs of SARS-CoV-2 in the tissue samples, suggesting the damage was not caused by a direct viral attack on the brain. The results were published as a correspondence in the New England Journal of Medicine.
“We found that the brains of patients who contract infection from SARS-CoV-2 may be susceptible to microvascular blood vessel damage. Our results suggest that this may be caused by the body’s inflammatory response to the virus” said Avindra Nath, M.D., clinical director at the NIH’s National Institute of Neurological Disorders and Stroke (NINDS) and the senior author of the study. “We hope these results will help doctors understand the full spectrum of problems patients may suffer so that we can come up with better treatments.”
They better should work together and make a hell of a combination